Investigation of cancer cell lines for peptide receptor-targeted drug development

Journal of Drug Targeting

Volumn 19, Issue 8, 2011, Pages 719-730

  Sun, Lichun ^a   Luo, Jing ^a   MacKey, L Vienna ^a   Morris, Lynsie M ^a   Franko Tobin, Laura G ^a   Lepage, Keith T ^a   Coy, David H ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Binding affinity; Cancer cell; Cytotoxic conjugate; GPCR; Peptide

Indexed keywords

BOMBESIN RECEPTOR; CPT SST; CYTOTOXIC AGENT; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BREAST CANCER; CANCER CELL CULTURE; CANCER SCREENING; CARCINOID; CELL SURFACE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DEVELOPMENT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; MOUSE; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BOMBESIN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; DRUG DISCOVERY; LIGANDS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, BOMBESIN; RECEPTORS, SOMATOSTATIN; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SOMATOSTATIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051748146     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.558089     Document Type: Article

References (44)

1. Anthony CT, Hughey S, Lyons J, Weiss S, Hornick CA, Drouant GJ, Fuselier JA, Coy DH, Murphy WA, Woltering EA. (2004). Te efect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs. J Surg Res, 119, 1-13. (Pubitemid 38581978)
2. Carter PJ, Senter PD. (2008). Antibody-drug conjugates for cancer therapy. Cancer J, 14, 154-169.
3. Eden PA, Taylor JE. (1993). Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci, 53, 85-90.
4. Engel JB, Schally AV, Dietl J, Rieger L, Hönig A. (2007). Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm, 4, 652-658. (Pubitemid 350004264)
5. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. (2005). Targeted cytotoxic bombesin analog AN-215 efectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer, 12, 999-1009. (Pubitemid 41815792)
6. Feron O. (2010). Tumor-penetrating peptides: a shift from magic bullets to magic guns. Sci Transl Med, 2, 34ps26.
7. Fuselier JA, Sun L, Woltering SN, Murphy WA, Vasilevich N, Coy DH. (2003). An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett, 13, 799-803. (Pubitemid 36255541)
8. Garrison JB, Shaw YJ, Chen CS, Kyprianou N. (2007). Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res, 67, 11344-11352. (Pubitemid 350248561)
9. Goldbard S. (2006). Bringing primary cells to mainstream drug development and drug testing. Curr Opin Drug Discov Devel, 9, 110-116. (Pubitemid 43099080)
10. Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S. (2010). Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett, 294, 35-42.
11. Horrocks C, Halse R, Suzuki R, Shepherd PR. (2003). Human cell systems for drug discovery. Curr Opin Drug Discov Devel, 6, 570-575. (Pubitemid 36975359)
12. Ioannou M, Papagelopoulos PJ, Papanastassiou I, Iakovidou I, Kottakis S, Demertzis N. (2008). Detection of somatostatin receptors in human osteosarcoma. World J Surg Oncol, 6, 99.
13. Kamb A. (2005). What's wrong with our cancer models? Nat Rev Drug Discov, 4, 161-165. (Pubitemid 40277495)
14. Khanna G, Bushnell D, O'Dorisio MS. (2008). Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist, 13, 382-389. (Pubitemid 351679917)
15. Knutsson M, Edvinsson L. (2002). Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport, 13, 507-509. (Pubitemid 34293200)
16. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET. (2004). Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med Oncol, 21, 285-295. (Pubitemid 39469770)
17. Ma C. (2004). Animal models of disease. Modern Drug Discov, 7, 30-34.
18. Mankof DA, Link JM, Linden HM, Sundararajan L, Krohn KA. (2008). Tumor receptor imaging. J Nucl Med, 49 (Suppl 2), 149S-163S. (Pubitemid 351948042)
19. Mezo G, Manea M. (2010). Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv, 7, 79-96.
20. Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, Gonzales N, Fuselier JA, Coy DH, Jensen RT. (2006). In vitro and in vivo antitumor efects of cytotoxic camptothecin-bombesin conjugates are mediated by specifc interaction with cellular bombesin receptors. J Pharmacol Exp Ter, 318, 1265-1272. (Pubitemid 44268334)
21. Nanda PK, Lane SR, Retzlof LB, Pandey US, Smith CJ. (2010). Radiolabeled regulatory peptides for imaging and therapy. Curr Opin Endocrinol Diabetes Obes, 17, 69-76.
22. Panetta R, Patel YC. (1995). Expression of mRNA for all fve human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci, 56, 333-342. (Pubitemid 124014542)
23. Patel YC. (1999). Somatostatin and its receptor family. Front Neuroendocrinol, 20, 157-198. (Pubitemid 29362641)
24. Rangarajan A, Weinberg RA. (2003). Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer, 3, 952-959. (Pubitemid 37500180)
25. Reubi JC. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 24, 389-427. (Pubitemid 37056239)
26. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. (2000). Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res, 60, 3105-3112. (Pubitemid 30395841)
27. Reubi JC, Maecke HR. (2008). Peptide-based probes for cancer imaging. J Nucl Med, 49, 1735-1738.
28. Schally AV, Nagy A. (1999). Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol, 141, 1-14. (Pubitemid 29370830)
29. Schally AV, Nagy A. (2003). New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci, 72, 2305-2320. (Pubitemid 36287676)
30. Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA. (2002). Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem, 2, 229-246.
31. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. (2010). Te role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal fndings on 111In-DTPA-octreotide scintigraphy. J Nucl Med, 51, 875-882.
32. Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R. (2006). Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer, 118, 222-229. (Pubitemid 41681603)
33. Sun B, Schally AV, Halmos G. (2000). Te presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept, 90, 77-84. (Pubitemid 30331013)
34. Sun L, Coy DH. (2008). Cytotoxic conjugates of peptide hormones for cancer chemotherapy. Drugs Future, 33, 217-223. (Pubitemid 351567920)
35. Sun L, Fuselier JA, Coy DH. (2004a). Efects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Deliv, 11, 231-238. (Pubitemid 39096041)
36. Sun L, Mackey LV, Luo J, Fuselier JA, Coy DH. (2008). Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol, 2, 491-499.
37. Sun L, Vasilevich NI, Fuselier JA, Coy DH. (2004b). Abilities of 3,4-diarylfuran-2-one analogs of combretastatin A-4 to inhibit both proliferation of tumor cell lines and growth of relevant tumors in nude mice. Anticancer Res, 24, 179-186. (Pubitemid 38279706)
38. Sun L, Vasilevich NI, Fuselier JA, Hocart SJ, Coy DH. (2004c). Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg Med Chem Lett, 14, 2041-2046. (Pubitemid 38481357)
39. Sun LC, Luo J, Mackey VL, Fuselier JA, Coy DH. (2007). Efects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs, 18, 341-348. (Pubitemid 46192989)
40. Szepeshazi K, Schally AV, Nagy A, Halmos G. (2005). Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas, 31, 275-282. (Pubitemid 41400486)
41. Teicher BA. (2009). Antibody-drug conjugate targets. Curr Cancer Drug Targets, 9, 982-1004.
42. Weinstein JN. (2006). Spotlight on molecular profling: "integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ter, 5, 2601-2605. (Pubitemid 44848986)
43. Xiao D, Wang J, Hampton LL, Weber HC. (2001). Te human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene, 264, 95-103. (Pubitemid 32195492)
44. Zwanziger D, Beck-Sickinger AG. (2008). Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des, 14, 2385-2400.